Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 421

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 421
---
,224,163 | ) |     |     249.6 | %  |
| Total other comprehensive income/(loss) |     |              1,569 |   |     |     42,308 |   |     |    (40,739 | ) |     |     (96.3 | )% |
| Total comprehensive loss for the year   |     |         (4,514,526 | ) |     | (1,249,624 | ) |     | (3,264,902 | ) |     |     261.3 | %  |
| Basic and diluted loss per share        |     |              (0.15 | ) |     |      (0.04 | ) |     |      (0.11 | ) |     |    (275.0 | )% |

____________ Notes: n.m. — not meaningful. Revenues Revenues decreased by $60,569, or 3.2%, from $1,879,939 for the year ended June 30, 2023, to $1,819,370 for the year ended June 30, 2024. Revenues from the Heritas Diagnostics segment decreased by $122,105, or 6.7%, from $1,824,664 for the year ended June 30, 2023, to $1,702,559, for the year ended June 30, 2024. This decline is attributable to a combination of volume and price effects: • volume effect: approximately 95.6% of the decline ($116,731) is due to a 6.4% reduction in testing volumes across key areas such as rare diseases, prenatal, and microbiome testing. Reduced customer demand, heightened competition, and evolving market conditions led to fewer tests performed; and • price effect: the remaining 4.4% of the decline ($5,374) is due to a 0.3% decrease in average pricing, which is quoted in U.S. dollars, driven by increased pricing pressures and competitive dynamics in the diagnostics market. In addition to these market -specificdynamics, macroeconomic factors exacerbated the decline. The transition of Argentina’s government from Alberto Fernández to Javier Milei in December 2023 brought significant economic reforms aimed at reducing inflation and stabilizing the economy. These reforms, however, gave rise to pricing volatility and reduced consumer purchasing power within the healthcare sector, further impacting demand for diagnostic products and services. Revenues from